LB Pharmaceuticals Inc
LBRX
$29.66
-$1.75-5.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.90M | 13.45M | 13.62M | 16.21M | 15.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.51M | 29.94M | 22.51M | 33.35M | 54.63M |
| Operating Income | -45.51M | -29.94M | -22.51M | -33.35M | -54.63M |
| Income Before Tax | -39.17M | -25.42M | -19.02M | -29.65M | -52.25M |
| Income Tax Expenses | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Earnings from Continuing Operations | -39.17 | -25.42 | -19.02 | -29.65 | -52.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.17M | -25.42M | -19.02M | -29.65M | -52.25M |
| EBIT | -45.51M | -29.94M | -22.51M | -33.35M | -54.63M |
| EBITDA | -45.19M | -29.62M | -22.19M | -33.10M | -54.46M |
| EPS Basic | -21.95 | -36.06 | -49.73 | -88.61 | -133.12 |
| Normalized Basic EPS | -12.97 | -22.00 | -31.19 | -56.37 | -44.46 |
| EPS Diluted | -21.95 | -36.06 | -49.73 | -88.61 | -133.12 |
| Normalized Diluted EPS | -12.97 | -22.00 | -31.19 | -56.37 | -44.46 |
| Average Basic Shares Outstanding | 59.71M | 31.82M | 6.78M | 1.33M | 1.08M |
| Average Diluted Shares Outstanding | 59.71M | 31.82M | 6.78M | 1.33M | 1.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |